Covid-19 Research

Rapid Communication

ASSUMER on PYP Scan for Cardiac Amyloid Typing and Origin: Case-Specific Corroborating Clinical Background and Genetic Analysis

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Rapid Communication
Subject Medicine Group
OCLC JBRES Record
Pipitsa Valsamaki*, Konstantinos Liapis, Vasileios Tsalkanis, Georgios Chalikias and Athanassios Zissimopoulos
Issue: Volume4-Issue1
Pages: 008-013
Received: 2022-12-27
Accepted: 2023-01-03
Published: 2023-01-05

Abstract

Suspicion for Cardiac Amyloidosis (CA) led a 75-year-old male patient with fatigue, dyspnea, and palpitations to be subjected to scintigraphic myocardial investigation with technetium-99m-pyrophosphate (99mTc-PYP, or PYP scan) in order to distinguish transthyretin-related CA (ATTR) from the light-chain Amyloidosis (AL) form. A characteristic anamnesis of bilateral carpal tunnel syndrome, vertebral canal stenosis, and senile cataract, as well as laboratory, Electrocardiographic (ECG), and echocardiographic exploration was compatible with a positive for ATTR PYP scan. Specific features on PYP scan, namely Apical Sparing, more marked Septal Uptake and an associated Equivalent cardiac retention, particularly heart-to-contralateral (H/CL) Ratio from 1 h to 3 h pi (“ASSUMER”) were coupled with a negative genetic analysis, verifying wild-type ATTR. The herein introduced “ASSUMER” on PYP scan could be a hallmark not only of the amyloid fibril subtype but also origin.

FullText HTML FullText PDF DOI: 10.37871/jbres1643 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2023 Valsamaki P, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Valsamaki P, Liapis K, Tsalkanis V, Chalikias G, Zissimopoulos A. “ASSUMER” on PYP Scan for Cardiac Amyloid Typing and Origin: Case-Specific Corroborating Clinical Background and Genetic Analysis. 2022 Jan 05; 4(1): 008-0013. doi: 10.37871/jbres1643, Article ID: JBRES1643, Available at: https://www.jelsciences.com/articles/jbres1643.pdf

Subject area(s)

Clinical Cardiology

References

  1. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014 Feb;99(2):209-21. doi: 10.3324/haematol.2013.087619. PMID: 24497558; PMCID: PMC3912950.
  2. Bistola V, Parissis J, Foukarakis E, Valsamaki PN, Anastasakis A, Koutsis G, Efthimiadis G, Kastritis E. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Fail Rev. 2021 Jul;26(4):861-879. doi: 10.1007/s10741-020-10062-w. Epub 2021 Jan 15. PMID: 33452596.
  3. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011 Oct 20;118(16):4346-52. doi: 10.1182/blood-2011-01-330738. Epub 2011 Aug 9. PMID: 21828140; PMCID: PMC3204906.
  4. Valsamaki PN, Zissimopoulos A. Cardiac amyloidosis. Two main subtypes and diagnosis by Nuclear Medicine: SPET tracer revival. Hell J Nucl Med. 2019 Sep-Dec;22(3):161-164. doi: 10.1967/s002449911050. Epub 2019 Oct 7. PMID: 31587024.
  5. Alperstein AM, Ostrander JS, Zhang TO, Zanni MT. Amyloid found in human cataracts with two-dimensional infrared spectroscopy. Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6602-6607. doi: 10.1073/pnas.1821534116. Epub 2019 Mar 20. PMID: 30894486; PMCID: PMC6452718.
  6. Bokhari S, Shahzad R, Castaño A, Maurer MS. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol. 2014 Feb;21(1):175-84. doi: 10.1007/s12350-013-9803-2. PMID: 24162886; PMCID: PMC4302756.
  7. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84. doi: 10.1016/j.jacc.2005.05.073. PMID: 16168294.
  8. Valsamaki P, Kastritis S, Delichas Z, Dimopoulos MA, Papantoniou V. Scintigraphy with 99mTc-pyrophosphate contributes in avoiding pitfalls by non-invasive diagnosis of TTR related cardiac amyloidosis. In Proceedings of 5th European Conference on Clinical and Medical Case Reports. 2017;7(8):32.
  9. Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, Lohse P, Röcken C. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012 Jan 12;119(2):488-93. doi: 10.1182/blood-2011-06-358507. Epub 2011 Nov 21. PMID: 22106346.
  10. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid. 2002 Jun;9(2):108-14. PMID: 12440483.
  11. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009 Dec 3;114(24):4957-9. doi: 10.1182/blood-2009-07-230722. Epub 2009 Oct 1. PMID: 19797517.
  12. Sperry BW, Vranian MN, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R, Phelan D, Cerqueira MD, Jaber WA. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):234-242. doi: 10.1016/j.jcmg.2017.06.020. Epub 2017 Oct 5. PMID: 28917675.
  13. Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci. 2016;121(1):17-24. doi: 10.3109/03009734.2015.1122687. Epub 2016 Feb 5. PMID: 26849806; PMCID: PMC4812053.
  14. Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017 Apr;281(4):337-347. doi: 10.1111/joim.12585. Epub 2017 Jan 17. PMID: 28093848.
  15. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation. 2012 May 27;93(10):1017-23. doi: 10.1097/TP.0b013e31824b3749. PMID: 22395298.
  16. Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson BO, Westermark P. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005 Jun;206(2):224-32. doi: 10.1002/path.1759. PMID: 15810051.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership